{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:55:09Z","timestamp":1787223309709,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Genomic and immunologic tumor biomarker testing has dramatically changed the prognosis of patients, particularly those treated for advanced\/metastatic non-squamous non-small-cell lung cancer (aNSCLC) when access to targeted agents is available. It remains unclear whether older patients have access to therapy-predictive biomarker testing techniques in the same proportion as younger patients. This study aims to compare the proportion of biomarker testing performed in non-squamous aNSCLC at diagnosis between patients aged \u226570 years old and their younger counterparts. Methods: We conducted a retrospective analysis using the Epidemio-Strategy and Medical Economics (ESME) Advanced or Metastatic Lung Cancer Data Platform, a French multicenter real-life database. All patients with non-squamous aNSCLC diagnosed between 2015 and 2018 were selected. Biomarker testing corresponded to at least one molecular alteration and\/or PD-L1 testing performed within 1 month before or 3 months after the aNSCLC diagnosis. Results: In total, 2848 patients aged \u226570 years and 6900 patients aged &lt;70 years were included. Most patients were male. The proportion of current smokers at diagnosis was higher in the &lt;70 years group (42% vs. 17%, p &lt; 0.0001). There was no significant difference in the proportion of biomarker testing performed between the two groups (63% vs. 65%, p = 0.15). EGFR mutations were significantly more common in the older group (22% vs. 12%, p &lt; 0.0001) and KRAS mutations significantly more frequent in the younger group (39% vs. 31% p &lt; 0.0001). The distribution of other driver mutations (ALK, ROS1, BRAF V600E, HER2, and MET) was similar across age. In the multivariable analysis, factors independently associated with biomarker testing were gender, smoking status, history of COPD, stage at primary diagnosis, and histological type. Conclusions: Age is not a barrier to biomarker testing in patients with aNSCLC.<\/jats:p>","DOI":"10.3390\/cancers14010092","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T01:00:54Z","timestamp":1640566854000},"page":"92","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience"],"prefix":"10.3390","volume":"14","author":[{"given":"Tina","family":"Lamy","sequence":"first","affiliation":[{"name":"D\u00e9partement D\u2019Oncologie M\u00e9dicale, Gustave Roussy, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Cabarrou","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Biostatistiques, Institut Claudius Regaud\u2014IUCT-O, 31059 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019Oncologie M\u00e9dicale, Gustave Roussy, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-3612","authenticated-orcid":false,"given":"Xavier","family":"Quantin","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Inserm U1194, Universit\u00e9 de Montpellier, Institut du Cancer Montpellier (ICM), 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Schneider","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre Hospitalier de la C\u00f4te Basque, 64100 Bayonne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bringuier","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019Oncologie M\u00e9dicale, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019Oncologie M\u00e9dicale, Gustave Roussy, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019Oncologie M\u00e9dicale, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre Hospitalier Intercommunal de Cr\u00e9teil, 94000 Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Biostatistiques, Institut Claudius Regaud\u2014IUCT-O, 31059 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-5005","authenticated-orcid":false,"given":"Ga\u00ebtane","family":"Simon","sequence":"additional","affiliation":[{"name":"Direction des Datas, Unicancer, 75654 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019Innovation Th\u00e9rapeutique et des Essais Pr\u00e9coces (DITEP), Gustave Roussy, 95805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends-An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cger.2017.06.008","article-title":"Lung Cancer in the Older Patient","volume":"33","author":"Barta","year":"2017","journal-title":"Clin. Geriatr. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.resinv.2018.10.003","article-title":"The clinical features of older patients with lung cancer in comparison with their younger counterparts","volume":"57","author":"Ogino","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.21037\/jtd.2019.11.11","article-title":"Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States","volume":"11","author":"Chen","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","article-title":"Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial","volume":"378","author":"Quoix","year":"2011","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study","volume":"13","author":"Ciuleanu","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(13)70310-3","article-title":"Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial","volume":"14","author":"Garassino","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non\u2013small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Annals Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e201250","DOI":"10.1001\/jamaoncol.2020.1250","article-title":"Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation\u2013Positive Non\u2013Small Cell Lung Cancer A Multicenter Phase 2 Trial","volume":"6","author":"Miyamoto","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non\u2013small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ003 study","volume":"7","author":"Maemondo","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2784-x","article-title":"Phase II study of erlotinib in elderly patients with non\u2013small cell lung cancer harboring epidermal growth factor receptor mutations","volume":"76","author":"Inoue","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2018.10.014","article-title":"A phase II study of afatinib treatment for elderly patients with previously untreated advanced non\u2013small-cell lung cancer harboring EGFR mutations","volume":"126","author":"Imai","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2007.15.2280","article-title":"Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR","volume":"26","author":"Ding","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using Multiplexed Assays of Oncogenic Driversin Lung Cancers to Select Targeted Drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2016.05.024","article-title":"Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing","volume":"107","author":"Doble","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/cncr.28604","article-title":"Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study","volume":"120","author":"Serizawa","year":"2014","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.21873\/cgp.20155","article-title":"Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment","volume":"16","author":"Linardou","year":"2019","journal-title":"Cancer Genom. Proteom."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/PAI.0000000000000678","article-title":"Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old","volume":"27","author":"Forest","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Brueckl, W.M., Achenbach, H.J., Ficker, J.H., and Schuette, W. (2018). Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice-results from the ElderTac study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4208-x"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/02841860500256215","article-title":"Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience","volume":"44","author":"Hotta","year":"2005","journal-title":"Acta Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/sj.bjc.6601470","article-title":"Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)","volume":"90","author":"Cappuzzo","year":"2004","journal-title":"Br. J. Cancer."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1634\/theoncologist.2019-0003","article-title":"Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial","volume":"24","author":"Nakao","year":"2019","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/92\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:53:10Z","timestamp":1760169190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["cancers14010092"],"URL":"https:\/\/doi.org\/10.3390\/cancers14010092","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]}}}